[go: up one dir, main page]

NO20080409L - Fremgangsmater og preparater til malsoking av IFNAR2 - Google Patents

Fremgangsmater og preparater til malsoking av IFNAR2

Info

Publication number
NO20080409L
NO20080409L NO20080409A NO20080409A NO20080409L NO 20080409 L NO20080409 L NO 20080409L NO 20080409 A NO20080409 A NO 20080409A NO 20080409 A NO20080409 A NO 20080409A NO 20080409 L NO20080409 L NO 20080409L
Authority
NO
Norway
Prior art keywords
methods
ifnar2
milling
preparations
antibodies
Prior art date
Application number
NO20080409A
Other languages
English (en)
Inventor
Anan Chuntharapai
Kerstin Schmidt
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of NO20080409L publication Critical patent/NO20080409L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

Sammendrag Monoklonale anti-IFNAR2-antistoffer og fremgangsmåter for å benytte antistoffene som blir tilveiebrakt.
NO20080409A 2005-06-22 2008-01-21 Fremgangsmater og preparater til malsoking av IFNAR2 NO20080409L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69278605P 2005-06-22 2005-06-22
PCT/US2006/023993 WO2007002096A2 (en) 2005-06-22 2006-06-21 Methods and compositions for targeting ifnar2

Publications (1)

Publication Number Publication Date
NO20080409L true NO20080409L (no) 2008-03-25

Family

ID=37514248

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20080409A NO20080409L (no) 2005-06-22 2008-01-21 Fremgangsmater og preparater til malsoking av IFNAR2

Country Status (13)

Country Link
US (1) US20070081995A1 (no)
EP (1) EP1893646A2 (no)
JP (1) JP2008543335A (no)
KR (1) KR20080031022A (no)
CN (1) CN101243105A (no)
AU (1) AU2006262289A1 (no)
BR (1) BRPI0613306A2 (no)
CA (1) CA2612378A1 (no)
IL (1) IL187587A0 (no)
MX (1) MX2007016343A (no)
NO (1) NO20080409L (no)
RU (1) RU2008102245A (no)
WO (1) WO2007002096A2 (no)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2219452B1 (en) * 2007-11-05 2015-10-14 MedImmune, LLC Methods of treating scleroderma
CN103952413B (zh) * 2014-05-14 2016-08-17 广东省农业科学院动物卫生研究所 靶向ifnar2基因的rna干扰表达载体构建及应用
WO2022087274A1 (en) * 2020-10-21 2022-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies that neutralize type-i interferon (ifn) activity

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ198445A (en) * 1980-09-25 1984-05-31 Genentech Inc Production of human fibroblast interferon by recombinant dna technology
US5516515A (en) * 1986-02-05 1996-05-14 Interferon Sciences, Inc. Separation of alpha interferon receptor proteins and antibodies therefor
US5889151A (en) * 1989-10-20 1999-03-30 Societe Leb-Tech Purified human alpha interferon receptor
EP0563487A1 (en) * 1992-03-31 1993-10-06 Laboratoire Europeen De Biotechnologie S.A. Monoclonal antibodies against the interferon receptor, with neutralizing activity against type I interferon
US5821078A (en) * 1992-09-03 1998-10-13 Yeda Research And Development Co. Ltd. Nucleic acid encoding interferon-α/β binding protein
IL106591A (en) * 1992-09-03 2008-03-20 Yeda Res & Dev Interferon alpha/beta binding protein, its preparation and pharmaceutical compositions containing it
IL108584A (en) * 1994-02-07 2008-03-20 Yeda Res & Dev Cloning of interferon -alpha/beta binding protein
IL107378A (en) * 1993-10-24 2005-05-17 Yeda Res & Dev SOLUBLE INTERFERON alpha-RECEPTOR, ITS PREPARATION AND USE
ATE390933T1 (de) * 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
EP0823941A4 (en) * 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
IL118096A0 (en) * 1996-05-01 1996-09-12 Yeda Res & Dev Antibodies against interferon alpha/beta receptor
US6713609B1 (en) * 1996-07-16 2004-03-30 Genentech, Inc. Monoclonal antibodies to type I interferon receptor
US20030018174A1 (en) * 1997-10-06 2003-01-23 Genentech, Inc. Monoclonal antibodies to IFNAR2
US7087726B2 (en) * 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies

Also Published As

Publication number Publication date
KR20080031022A (ko) 2008-04-07
WO2007002096A3 (en) 2007-05-10
CA2612378A1 (en) 2007-01-04
RU2008102245A (ru) 2009-07-27
JP2008543335A (ja) 2008-12-04
IL187587A0 (en) 2008-03-20
CN101243105A (zh) 2008-08-13
BRPI0613306A2 (pt) 2010-12-28
US20070081995A1 (en) 2007-04-12
AU2006262289A1 (en) 2007-01-04
EP1893646A2 (en) 2008-03-05
MX2007016343A (es) 2008-03-05
WO2007002096A2 (en) 2007-01-04

Similar Documents

Publication Publication Date Title
NO20083127L (no) Fremgangsmater og preparater for malretting av polyubiquitin
HUS2300026I1 (hu) Anti-CTLA-4 ellenanyag készítmények
NO20083147L (no) Anti-OX40L-antistoffer og fremgangsmater for anvendelse av disse
NO20083397L (no) Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse
NO20090047L (no) Anti-DLL4-antistoffer og fremgangsmater for anvendelse av disse
CY1118343T1 (el) Αντισωματα συνδεσης twεακ
NO20084356L (no) Anti TAT226-antistoffer og immunokonjugater
DK1553975T3 (da) Optimerede Fc-varianter og fremgangsmåder til generering heraf.
NO20043564L (no) Follistatindomene som inneholder proteiner
BRPI0510674A (pt) variantes fc otimizadas
NO20092052L (no) Antistoffer og immunkonjugater, og anvendelser derav
CY1111622T1 (el) Ανθρωποποιημενοι ανταγωνιστες anti-cmet
BR122018016045B8 (pt) proteína variante otimizada
NO20085396L (no) Antistoffer og immunkonjugater, og anvendelser derav
NL1027975A1 (nl) Antilichamen tegen MAdCAM.
UA95768C2 (ru) Антагонисты мускариновых рецепторов ацетилхолина
MX2007002675A (es) Antagonistas anti-beta7 humanizados y usos para los mismos.
WO2007008943A3 (en) Optimized anti-ep-cam antibodies
EA200702278A1 (ru) Антитела, специфичные в отношении tgf-бета 1
NO20083593L (no) Anti-EphrinB2-antistoffer og fremgangsmater for anvendelse av disse
BRPI0512235A (pt) polipeptìdeos ligadores de antìgenos e seus usos
ATE459706T1 (de) Monoklonales antikörper gegen das hcv kernantigen
WO2006083936A3 (en) Anti-ephb2 antibodies and methods using same
NO20090333L (no) Fremgangsmater og preparater rettet mot hepsin
NO20075140L (no) Fremgangsmater og preparater for modulering av vaskulaer integritet

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application